Regeneron Pharmaceuticals (REGN) Common Equity (2009 - 2026)

Regeneron Pharmaceuticals has reported Common Equity for 18 years, with the latest figure at $31.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 6.93% year-over-year to $31.4 billion; the trailing twelve-month figure through Mar 2026 stood at $31.4 billion (up 6.93% YoY), and the FY2025 full-year result was $31.3 billion, up 6.48% from the prior year.
• Common Equity for Q1 2026 stood at $31.4 billion, up from $31.3 billion in the prior quarter.
• The five-year high for Common Equity was $31.4 billion in Q1 2026, with the low at $19.9 billion in Q1 2022.
• Average Common Equity over 5 years is $26.5 billion, with a median of $27.0 billion recorded in 2024.
• Year-over-year, Common Equity surged 66.27% in 2022 and climbed 5.56% in 2025.
• Tracing REGN's Common Equity over 5 years: stood at $22.7 billion in 2022, then climbed by 14.6% to $26.0 billion in 2023, then increased by 13.02% to $29.4 billion in 2024, then increased by 6.48% to $31.3 billion in 2025, then increased by 0.53% to $31.4 billion in 2026.
• The last three Common Equity figures came in at $31.4 billion (Q1 2026), $31.3 billion (Q4 2025), and $31.0 billion (Q3 2025), per Business Quant data.

Peer Comparison